Early mortality in lung cancer: French prospective multicentre observational study, Disponible sur, 4818853. ,
DOI : 10.1016/j.lungcan.2010.03.003
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), The Lancet, vol.387, issue.10026, pp.1415-1441, 2016. ,
DOI : 10.1016/S0140-6736(16)00004-0
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non???Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy, Journal of Clinical Oncology, vol.18, issue.10, pp.2095-103, 2000. ,
DOI : 10.1200/JCO.2000.18.10.2095
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non???Small-Cell Lung Cancer Previously Treated With Chemotherapy, Journal of Clinical Oncology, vol.22, issue.9, pp.1589-97, 2004. ,
DOI : 10.1200/JCO.2004.08.163
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial, The Lancet, vol.384, issue.9944, pp.665-73, 2014. ,
DOI : 10.1016/S0140-6736(14)60845-X
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial, The Lancet Oncology, vol.15, issue.2, pp.143-55, 2014. ,
DOI : 10.1016/S1470-2045(13)70586-2
Erlotinib in Previously Treated Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.353, issue.2, pp.123-155, 2005. ,
DOI : 10.1056/NEJMoa050753
Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE, Disponible sur, pp.167643-176, 2017. ,
Oncology Meets Immunology: The Cancer-Immunity Cycle, Immunity, vol.39, issue.1, pp.1-10, 2013. ,
DOI : 10.1016/j.immuni.2013.07.012
The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment, Oral Oncology, vol.61, pp.152-160, 2016. ,
DOI : 10.1016/j.oraloncology.2016.08.001
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial, The Lancet Oncology, vol.16, issue.3, pp.257-65, 2015. ,
DOI : 10.1016/S1470-2045(15)70054-9
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.373, issue.2, 2015. ,
DOI : 10.1056/NEJMoa1504627
Nivolumab versus Docetaxel in Advanced Nonsquamous Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.373, issue.17, pp.1627-1666, 2015. ,
DOI : 10.1056/NEJMoa1507643
OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057, Journal of Thoracic Oncology, vol.12, issue.1, p.253, 2017. ,
DOI : 10.1016/j.jtho.2016.11.241
Efficacit?? des inhibiteurs du checkpoint immunitaire PD-1/PD-L1??et testing PD-L1??dans les cancers thoraciques, Annales de Pathologie, vol.37, issue.1, pp.61-78, 2017. ,
DOI : 10.1016/j.annpat.2016.12.009
Nivolumab Monotherapy for First-Line Treatment of Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.34, issue.25 ,
DOI : 10.1200/JCO.2016.66.9929
NSCLC, metastaticCheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)???positive NSCLC, Annals of Oncology, vol.27, issue.suppl_6, p.2016, 2017. ,
DOI : 10.1093/annonc/mdw435.39
Pembrolizumab versus Chemotherapy for PD-L1???Positive Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.375, issue.19, pp.1823-1856, 2016. ,
DOI : 10.1056/NEJMoa1606774
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, vol.9, issue.7528, pp.563-570, 2014. ,
DOI : 10.1371/journal.pone.0088401
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, The Lancet, vol.387, issue.10030, 2016. ,
DOI : 10.1016/S0140-6736(16)00587-0
Tumor's flare-up and patterns of recurrence in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with anti-PD1/PD-L1 inhibitors, J Clin Oncol, vol.34, pp.6072-6072, 2016. ,
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1, Clinical Cancer Research, vol.23, issue.8, 2017. ,
DOI : 10.1158/1078-0432.CCR-16-1741
Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges, European Journal of Cancer, vol.78, pp.16-23, 1990. ,
DOI : 10.1016/j.ejca.2016.12.041
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non???Small-Cell Lung Cancer, JAMA Oncology, vol.2, issue.1, pp.46-54, 2016. ,
DOI : 10.1001/jamaoncol.2015.3638
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies, Annals of Oncology, vol.27, issue.1, pp.147-53, 2016. ,
DOI : 10.1093/annonc/mdv489
Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non???Small-Cell Lung Cancer, Clinical Lung Cancer, vol.16, issue.5, pp.385-90, 2015. ,
DOI : 10.1016/j.cllc.2015.03.008
Programmed Cell Death Ligand (PD-L1) Expression in??Stage II and III Lung Adenocarcinomas and Nodal??Metastases, Journal of Thoracic Oncology, vol.12, issue.3, pp.458-66, 2017. ,
DOI : 10.1016/j.jtho.2016.10.015
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma, Cancer Immunology Research, vol.3, issue.10, pp.1158-64, 2015. ,
DOI : 10.1158/2326-6066.CIR-15-0043
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer, Cell Death and Differentiation, vol.118, issue.1, pp.15-25, 2014. ,
DOI : 10.1172/JCI34333
Radiotherapy complements immune checkpoint blockade. Cancer Cell. 13 avr 2015, pp.437-445 ,
Pembrolizumab for the Treatment of Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.372, issue.21, 2015. ,
DOI : 10.1056/NEJMoa1501824
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients, Virchows Archiv, vol.20, issue.Suppl 3, pp.511-536, 2016. ,
DOI : 10.1158/1078-0432.CCR-14-0933
??valuation de l???expression de PD-L1 en immunohistochimie??: un biomarqueur ??mergent dans les carcinomes pulmonaires non ?? petites cellules, Annales de Pathologie, vol.36, issue.1, pp.94-102, 2016. ,
DOI : 10.1016/j.annpat.2015.11.004
PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells, Cancer Immunology Research, vol.3, issue.12, pp.1308-1323, 2015. ,
DOI : 10.1158/2326-6066.CIR-15-0116
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy, Molecular Cancer Therapeutics, vol.14, issue.4, pp.847-56, 2015. ,
DOI : 10.1158/1535-7163.MCT-14-0983
Enjeux et limites actuelles de l?????valuation du statut de PD-L1??par immunohistochimie sur des biopsies bronchiques, Bulletin du Cancer, vol.103, issue.4, pp.368-80, 2016. ,
DOI : 10.1016/j.bulcan.2016.01.014
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non???Small Cell Lung Cancer, Clinical Cancer Research, vol.23, issue.14, 2017. ,
DOI : 10.1158/1078-0432.CCR-16-2375
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas, Modern Pathology, vol.85, issue.10, pp.1165-72, 2016. ,
DOI : 10.1200/JCO.2014.58.1041
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project, Journal of Thoracic Oncology, vol.12, issue.2, pp.208-230, 2017. ,
DOI : 10.1016/j.jtho.2016.11.2228
An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1, Molecular Diagnosis & Therapy, vol.23, issue.Suppl 1, pp.85-93, 2017. ,
DOI : 10.1097/PAI.0000000000000256
Multiinstitutional , Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD- L1 Expression in Non?Small Cell Lung Cancer, Disponible sur, p.2017, 2017. ,
Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system, Histopathology, vol.1, issue.Suppl. 2, pp.253-63, 2017. ,
DOI : 10.1080/23808993.2016.1140005
Programmed death ligand-1 expression in non-small cell lung cancer, Laboratory Investigation, vol.0959, issue.8049, pp.107-123, 2014. ,
DOI : 10.1126/scitranslmed.3006504
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis, Oncotarget, vol.7, issue.15, pp.19738-19785, 2016. ,
DOI : 10.18632/oncotarget.7582
Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis, Critical Reviews in Oncology/Hematology, vol.101, pp.75-85, 2016. ,
DOI : 10.1016/j.critrevonc.2016.03.007
The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis, Immunotherapy, vol.33, issue.3, pp.479-88, 2016. ,
DOI : 10.1056/NEJMoa1200690
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients, British Journal of Cancer, vol.49, issue.1, pp.95-102, 2015. ,
DOI : 10.1038/nri2326
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria, Clinical Cancer Research, vol.15, issue.23, pp.7412-7432, 2009. ,
DOI : 10.1158/1078-0432.CCR-09-1624
Evolution of Neoantigen Landscape During Immune Checkpoint Blockade in Non-Small Cell Lung Cancer, Cancer Discov. 1 janv, pp.16-0828, 2017. ,
Epigenetics and immunotherapy: The current state of play, Molecular Immunology, vol.87, pp.227-266, 2017. ,
DOI : 10.1016/j.molimm.2017.04.012
Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy, Clinical Cancer Research, vol.21, issue.18, pp.4040-4047, 2015. ,
DOI : 10.1158/1078-0432.CCR-14-2914
Expression of antigen processing and presenting molecules in brain metastasis of breast cancer, Cancer Immunology, Immunotherapy, vol.128, issue.2, pp.789-801, 2012. ,
DOI : 10.1002/ijc.25613
Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer, Cancer Medicine, vol.33, issue.10027, 2016. ,
DOI : 10.1148/rg.352140121
Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation, Translational Lung Cancer Research, vol.6, issue.2, pp.148-58, 2017. ,
DOI : 10.21037/tlcr.2017.03.06
Innate and adaptive immune cells in the tumor microenvironment, Nature Immunology, vol.179, issue.10, pp.1014-1036, 2013. ,
DOI : 10.1016/j.ijrobp.2012.12.025
The emerging role of T cell cytokines in non-small cell lung cancer, Cytokine & Growth Factor Reviews, vol.23, issue.6, pp.315-337, 2012. ,
DOI : 10.1016/j.cytogfr.2012.08.009
Immunosuppressive effect of regulatory T lymphocytes in lung cancer, with special reference to their effects on the induction of autologous tumor-specific cytotoxic T lymphocytes, Oncol Lett. oct, vol.4, issue.4, pp.625-655, 2012. ,
Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients, Cancer, vol.310, issue.12, pp.2866-72, 2006. ,
DOI : 10.1159/000386035
A High Number of CD8+ T Cells Infiltrated in NSCLC Tissues is Associated With a Favorable Prognosis, Applied Immunohistochemistry & Molecular Morphology, vol.18, issue.1, pp.24-32, 2010. ,
DOI : 10.1097/PAI.0b013e3181b6a741
The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies, The Journal of Pathology, vol.7, issue.3, pp.254-65, 2002. ,
DOI : 10.1038/sj.gt.3301058
Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy, European Journal of Cancer, vol.42, issue.6, pp.717-744, 1990. ,
DOI : 10.1016/j.ejca.2006.01.003
Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression, Journal of Laboratory and Clinical Medicine, vol.140, issue.5, pp.320-328, 2002. ,
DOI : 10.1067/mlc.2002.128317
Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer, British Journal of Cancer, vol.73, issue.2, pp.148-53, 1996. ,
DOI : 10.1038/bjc.1996.28
Alteration of the immunological synapse in lung cancer: a microenvironmental approach, Clinical & Experimental Immunology, vol.288, issue.1, pp.48-55, 2008. ,
DOI : 10.1164/ajrccm/139.2.330
The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture, Vaccines, vol.256, issue.1, p.7, 2017. ,
DOI : 10.1016/S0074-7696(07)56005-5
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer, Nature Medicine, vol.166, issue.7, pp.828-863, 2007. ,
DOI : 10.4049/jimmunol.166.9.5398
The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration, International Journal of Cancer, vol.375, issue.4, pp.888-99, 2017. ,
DOI : 10.1056/NEJMoa1604958
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation, Frontiers in Immunology, vol.4, issue.12, 5149523. ,
DOI : 10.1186/s40425-016-0118-0
The blockade of immune checkpoints in cancer immunotherapy, Nature Reviews Cancer, vol.12, issue.4, pp.252-64, 2012. ,
DOI : 10.1038/nrc3237
PD1 signal transduction pathways in T cells, Oncotarget, vol.5, issue.0, 2017. ,
DOI : 10.18632/oncotarget.17232
Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses, Immunity, vol.27, issue.1, pp.111-133, 2007. ,
DOI : 10.1016/j.immuni.2007.05.016
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1), Proceedings of the National Academy of Sciences, vol.179, issue.5, pp.20852-20859, 2008. ,
DOI : 10.4049/jimmunol.179.5.2860
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape, Science Translational Medicine, vol.27, issue.36, pp.127-164, 2012. ,
DOI : 10.1200/JCO.2009.23.4799
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells ,
Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non, Small Cell Lung Cancer. Sci Rep. 17 août, vol.5, p.13110, 2015. ,
Selective Survival of Naturally Occurring Human CD4+CD25+Foxp3+ Regulatory T Cells Cultured with Rapamycin, The Journal of Immunology, vol.178, issue.1, pp.320-329, 2007. ,
DOI : 10.4049/jimmunol.178.1.320
The PD-1 pathway in tolerance and autoimmunity, Immunological Reviews, vol.183, issue.1, pp.219-261, 2010. ,
DOI : 10.4049/jimmunol.176.5.3000
Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets, The Journal of Immunology, vol.186, issue.6, pp.3299-303, 1950. ,
DOI : 10.4049/jimmunol.1003613
Regulatory T cells as suppressors of anti-tumor immunity: Role of metabolism, Cytokine & Growth Factor Reviews, vol.35, pp.15-25, 2017. ,
DOI : 10.1016/j.cytogfr.2017.04.001
Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation, Seminars in Cancer Biology, vol.43, pp.74-89, 2017. ,
DOI : 10.1016/j.semcancer.2017.03.001